Lead sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of November 5, 2026.
3
Trials led
3
Ongoing
704
Total enrollment
3
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
2
Trials by status
Not yet recruiting
2
Active, not recruiting
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.BMI ≤40Ph 2Not yet recruiting360
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or MetforminBMI ≤40Ph 2Not yet recruiting240